Also found in: Dictionary, Wikipedia.


any of a group of related phosphorus-containing compounds that are structurally similar to pyrophosphate but have enhanced stability to enzymatic and chemical hydrolysis and have affinity for sites of osteoid mineralization. They are used as sodium salts to inhibit bone resorption as well as complexed with technetium Tc 99m for bone imaging. The group includes alendronate, etidronate, and pamidronate. Called also bisphosphonate.


Member of a class of drugs used for treatment of osteoporosis; works by inhibiting osteoclast-mediate resorption of bone.


/bis·phos·pho·nate/ (bis-fos´fo-nāt) diphosphonate.


Any of a class of drugs that decrease bone resorption by inhibiting osteoclasts, used in the treatment of osteoporosis, Paget's disease, bone metastases, and other conditions. Also called diphosphonate.




Any of a family of drugs with two phosphonate (PO3) groups, which inhibit enzymes that break down pyrophosphate. Bisphosphonates include etidronate and clodronate (first-generation agents), and pamidronate disodium (a second-generation bisphosphonate), which inhibits bone resorption at doses that do not affect bone mineralisation. Bisphosphonates are potent inhibitors of bone resorption that bind tightly to the hydroxyapatite crystals, and have therapeutic potential in osteoporosis and in advanced (stage-III) multiple myeloma and Paget’s disease of bone.

Treat and prevent osteoporosis, osteolysis due to metastatic breast and prostate cancer, multiple myeloma, Paget's disease of bone, fibrous dysplasia, Gaucher's disease, etc.

Adverse effect
Upset stomach, gastritis, oesophageal erosions; long-term effects include femoral fractures and an increased risk of oesophageal cancer.

Etidronate, clodronate, tiludronate.


A class of drugs used to treat Paget's disease. These drugs bind to the minerals in bone tissue and lessen the amount of bone loss associated with Paget's disease.


Member of a class of drugs used for treatment of osteoporosis; works by inhibiting osteoclast-mediate resorption of bone. bisphosphonate

bisphosphonate (bisfos´fənōt),

n brand names: Fosamax, Didrone;
drug class: two classes: the N-containing (atendronate) and non-N-containing (Etidronate);
action: used to inhibit bone resorption;
uses: prevention and treatment of osteoporosis, osteitis deformans (“Paget's disease of bone”), bone metastasis (with or without hypercalcemia), multiple myeloma and other conditions that feature bone fragility. Can rarely cause osteonecrosis of the jaw; this may be reason to postpone drug treatment until after dental treatment, as they remain bound to the bone for a prolonged period. Most cases occur in high-dose intravenous types used in cancer patients, but a small proportion happens in patients on oral types. Also called
diphosphonate. See also osteonecrosis, bisphosphonate-associated (BON).
References in periodicals archive ?
After the radiographical evaluation, bisphosphonate treatment was stopped and bed rest was advised.
The researchers compared 1,964 women who subsequently started bisphosphonate therapy with 1,964 propensity score-matched women who did not.
Researchers reviewed existing literature and Medicare data to determine distal radius fracture incidence and age-specific hip fracture rates after distal radius fracture with and without bisphosphonate treatment.
The use of nitrogenous bisphosphonates was associated with a nearly 50% reduction in the incidence of endometrial cancer among women in the PLCO, or Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.
patients who received continuous bisphosphonate treatment for 6 or more years result in fracture rates ranging from 9.
The first bisphosphonate used in humans was etidronate for myositis ossification.
The study shows that local bisphosphonate improves implant stability, meaning that the time until normal chewing function could be shortened, thus reducing the suffering for the patient," says Professor Per Aspenberg, Linkoping University Hospital, co-founder of AddBIO.
Bisphosphonates are used to prevent bone loss in metastatic disease.
More isn't better: Women who took a bisphosphonate for five years and then stopped had no fewer fractures than women who stayed on the drug for another five years.
Several cases of atypical fractures associated with long-term bisphosphonate therapy have been reported in the proximal femoral shaft with minimal or no trauma.
Bisphosphonates like Fosamax and Actonel are contributing to broken bones.
At the time, I had been taking a bisphosphonate for five years.